Pharmacogenomic Research in Korean Patients With Hepatitis C
NCT ID: NCT01453244
Last Updated: 2013-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
373 participants
OBSERVATIONAL
2011-07-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
NCT02597270
Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C
NCT00876174
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
NCT00543244
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
NCT01437969
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SVR group
A patients who achieved SVR (sustained virologic response)
No interventions assigned to this group
non-SVR group
A patients who not achieved SVR (sustained virologic response)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* HCV infected patients previously treated with antiviral drugs
* Patients had a history of autoimmune hemolytic anemia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inje University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jae-Gook Shin
Jae-Gook Shin
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jae-Gook Shin, M.D, phD
Role: PRINCIPAL_INVESTIGATOR
Inje University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inje University
Busan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.